A nanoparticle and its application

By combining the anticancer drug AMG510 with mannose or glucose-modified sugar polymer nanoparticles, the problems of treatment resistance in KRASG12C-mutant colorectal cancer and heterogeneity of the EPR effect of nanomedicines were solved, achieving efficient penetration and targeted delivery to the tumor site, enhancing the therapeutic effect and reducing the amount of drug used and the cost.

CN119700707BActive Publication Date: 2026-11-10FUDAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411831762.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2024-11-29
Filing Date
2024-12-12
Publication Date
2026-11-10
Estimated Expiration
2044-12-12

AI Technical Summary

Technical Problem

Existing treatments for KRASG12C-mutant colorectal cancer exhibit treatment resistance, and traditional nanomedicines show strong heterogeneity in their EPR effect during tumor treatment, making it difficult to achieve effective drug penetration and targeted delivery.

Method used

By combining the anticancer drug AMG510 with mannose or glucose-modified sugar polymer nanoparticles to form AMG510@M-NP or AMG510@G-NP, the tumor microenvironment can be reprogrammed to improve drug penetration and targeted delivery at the tumor site.

Benefits of technology

It improves drug penetration at the tumor site, reduces the actual dosage, lowers adverse drug reactions, enhances anti-cancer effects, and reduces production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005185711590000091
    Figure BDA0005185711590000091
  • Figure BDA0005185711590000101
    Figure BDA0005185711590000101
  • Figure BDA0005185711590000151
    Figure BDA0005185711590000151
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically relating to a glycopolymer nanoparticle and its applications. This invention encapsulates the anticancer drug AMG510 in mannose, which can reprogram the tumor microenvironment and increase drug penetration into the tumor. The synthesized glycopolymer nanoparticles AMG510@M-NP are hydrophilic and easily absorbed in vivo, reducing the actual dosage required at the theoretical drug level and further mitigating adverse drug reactions. Mannose and AMG510 exhibit a synergistic effect, enhancing the anticancer efficacy. Furthermore, mannose is readily available, the preparation process is simple, costs are reduced, and it is suitable for mass production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to a sugar polymer nanoparticle and its application. Background Technology

[0002] Colorectal cancer (CRC) is a common malignant tumor of the digestive tract and the third most common malignant tumor worldwide. It ranks third in incidence among men and second among women (Li Daojuan, Li Qian, He Yutong. Epidemiological trends of colorectal cancer [J]. Cancer Prevention and Control Research, 2015.). In 2018, there were over 1.8 million new cases and approximately 881,000 deaths worldwide (Tian Chuanxin, Zhao Lei. Epidemiological characteristics of colorectal cancer and liver metastasis [J]. Chinese Journal of Cancer Prevention and Control, 2021.). Although traditional therapies such as surgery, radiotherapy, and chemotherapy have some efficacy in the early stages of CRC, their effectiveness is limited in the late stages or in cases with specific gene mutations. The mortality rate of colorectal cancer remains high, necessitating continuous exploration of new treatment modalities (Zhai Jianning, Wang Xicheng, Wu Aiwen. Advances in colorectal cancer treatment in 2022 [J]. Electronic Journal of Comprehensive Cancer Treatment, 2023.).

[0003] KRAS mutations are a common gene mutation in a variety of cancers, particularly pancreatic cancer, colorectal cancer, and non-small cell lung cancer (NSCLC). The KRAS gene encodes a small GTPase, which plays a crucial role in cell signaling, especially in regulating cell growth and differentiation (S). J. Drábek et al. “Clinical Relevance of KRAS in Human Cancers.” Journal of Biomedicine and Biotechnology, 2010.). KRAS mutations typically lead to persistent activation, thereby promoting tumor development. They often result in aberrant activation of the MAPK pathway, leading to decreased patient survival (Andreas C. Damianou, Zhu Liang et al. “Interplay Between KRAS and LZTR1 Protein Turnover, Controlled by CUL3 / LZTR1 E3 Ubiquitin Ligase, is Disrupted by KRAS Mutations.” bioRxiv, 2021.).

[0004] However, despite the significant oncogenic role of KRAS mutations in various cancers, their treatment has remained challenging. Due to the unique structure of the KRAS protein and the lack of obvious binding sites, it has long been considered an "untreatable" target (Hu Jiarui, Li Zhanlin. Research progress on biological characteristics, clinical treatment and prognosis of KRAS-mutant advanced non-small cell lung cancer [J]. Chinese Journal of Oncology, 2023.). However, with in-depth research into the mechanisms of KRAS mutations, scientists have discovered several potential therapeutic strategies, including small molecule inhibitors targeting KRAS GTPase activity and the development of combination therapies utilizing signaling pathway alterations caused by KRAS mutations (M. Molina-Arcas, D. Hancock et al. "Abstract 4163: Determination of synthetic lethal interactions in KRAS oncogene dependent cancer cells reveals novel therapeutic targeting strategies." Cancer Research, 2012.).

[0005] KRAS mutant allele KRAS G12C This leads to the persistence of KRAS protein in its GDP-bound inactive state, thereby activating downstream MAPK and PI3K signaling pathways and promoting tumor cell survival and proliferation (A. Chour, A. Toffart et al. "Mechanisms of resistance to KRAS G12C inhibitors in KRAS"). G12C -mutated non-small cell lung cancer.”Frontiers in Oncology, 2024.). In recent years, research has focused on KRAS. G12C Significant progress has been made in the development of inhibitors for mutations. For example, MRTX849 and ARS-853 are two KRAS inhibitors that have been developed. G12C Selective covalent inhibitors, they work by interacting with KRAS G12CThe mutated cysteine ​​residues bind to the KRAS, preventing its activation and inhibiting downstream signal transduction (J. Christensen, Jill Hallin et al. "The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients." Cancer Discovery, 2019.; M. Patricelli, MRJanes et al. "Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State." Cancer Discovery, 2016.). AMG510 is a representative drug of these inhibitors, with an objective response rate (ORR) of only 9.7% in CRC. Even when used in combination with panitumumab, the ORR was only 30.0%. These drugs have shown promising antitumor activity in preclinical models and some patients, and have also demonstrated enhanced effects in combination therapy strategies (James G Christensen, Peter Olson et al. "Targeting Krasg12c-mutant cancer with a mutation-specific inhibitor." Journal of Internal Medicine, 2020.; Kevin Lou, V. Steri et al. "KRASG12C inhibition produces a driver-limited state revealing collateral dependencies." Science Signaling, 2019.). However, despite these inhibitors achieving positive responses in some patients, treatment resistance remains a major challenge. Furthermore, many combination therapy regimens with AMG510 are being evaluated at different stages of clinical trials, such as the combination of anti-PD-1 antibodies with AMG510, aiming to improve treatment efficacy by remodeling the tumor microenvironment; however, none have achieved satisfactory efficacy. This indicates that KRAS... G12C Treatment for mutant CRC still needs further optimization.

[0006] Nanotechnology, with its unique physical and chemical properties, has shown great potential in cancer treatment, particularly in drug delivery systems. On one hand, nanoparticles, once inside the body, circulate throughout the body and accumulate or release drug loads within tumors for localized therapy. On the other hand, they can significantly improve drug solubility, stability, and bioavailability, thereby enabling targeted drug delivery, minimizing systemic toxicity, and maximizing therapeutic relevance and efficiency. Furthermore, these systems can increase drug accumulation in tumor tissue through passive and active targeting. The EPR effect refers to the phenomenon where nanomedicines can penetrate from the bloodstream into tumor tissue and remain there for an extended period due to the high permeability of tumor blood vessels and poor lymphatic drainage (U. Prabhakar, H. Maeda et al. “Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology..” Cancer research, 2013.). This phenomenon provides a theoretical basis for the passive targeting of nanomedicines in tumor therapy (Elizabeth Huynh, G. Zheng. "Cancernanomedicine: addressing the dark side of the enhanced permeability and retention effect." Nanomedicine, 2015.). However, the EPR effect exhibits significant heterogeneity among different types of tumors and different patients (Jooho Park, Yongwhan Choi et al. "Alliance with EPR effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment." Theranostics, 2019.). Therefore, reprogramming the tumor microenvironment can increase drug penetration into tumors, providing new treatment options.

[0007] Mannose, as a biocompatible natural monosaccharide, possesses excellent drug delivery capabilities and can improve delivery efficiency. Mannose-modified nanoparticles, due to their specific targeting ability, good biocompatibility (Zhou Lin, Zhu Li, Chen Li, et al. Effects of mannose-modified chitosan on macrophage uptake of nanoparticles [J]. Journal of Suzhou University (Medical Edition), 2011.), safety, multifunctionality, and stability, show broad application potential in drug delivery, disease treatment, and biomedical research. Mannose-modified nanoparticles can specifically target cells expressing mannose receptors, such as macrophages (Zhou Lin, Zhu Li, Chen Li, et al. Effect of mannose-modified chitosan on macrophage uptake of nanoparticles [J]. Journal of Soochow University (Medical Edition), 2011.), tumor-associated macrophages (TAMs) (Liu Yu. Study on the binding ability of mannose-modified chitosan nanoparticles to tumor tissue [D]. Luzhou Medical College, 2015.), and M2 macrophages (Huang Yan, Jiang Ou, Wen Qinglian, et al. Experimental study on the targeted binding of mannose-modified carboxymethyl chitosan and etidronate complex nanoparticles to M2 macrophages [J]. Progress in Cancer, 2018.). This specific binding ability makes mannose-modified nanoparticles an effective drug delivery system, especially in tumor therapy (Huang Yan. Preliminary study on the antitumor effect of mannose-modified imidazole carboxymethyl chitosan and etidronate complex nanoparticles in animals [D]. Southwest Medical University, 2018.) and anti-inflammatory therapy. For example, mannose-modified superparamagnetic iron oxide nanoparticles can target macrophages by specifically binding to mannose receptors on the surface of macrophages (Qing Xin. Mannose-modified iron oxide nanoparticles alleviate chemotherapy-induced peripheral neuropathic pain [D]. Anhui Medical University, 2022.). Currently, there is very little research on oral administration of mannose materials. Therefore, combining AMG510 with mannose to prepare a new oral drug formulation for cancer treatment has clinical significance and market potential. Summary of the Invention

[0008] This invention discovers that combining anticancer drugs with glycopolymers can reprogram the tumor microenvironment and increase drug penetration into the tumor. Based on this, this invention was completed.

[0009] In a first aspect, the present invention provides a glycopolymer nanoparticle with the structural formula M@S-NP; wherein M is an antitumor drug and S-NP is a glycopolymer; the antitumor drug is encapsulated inside the glycopolymer to form the glycopolymer nanoparticle.

[0010] Furthermore, the sugar polymer is selected from mannose and / or glucose; mannose is preferred.

[0011] Furthermore, the antitumor drug is selected from one or more of AMG510, MRTX849 and / or ARS1620; preferably AMG510.

[0012] In one embodiment of the present invention, when the sugar polymer is mannose and the antitumor drug is AMG510, the formed sugar polymer nanoparticles are AMG510@M-NP; when the sugar polymer is glucose and the antitumor drug is AMG510, and the cancer treatment drug is AMG510, the formed sugar polymer nanoparticles are AMG510@G-NP.

[0013] In a second aspect, the present invention provides a pharmaceutical composition comprising the glycopolymer nanoparticles as described in the first aspect.

[0014] Furthermore, the sugar polymer is selected from mannose and / or glucose; mannose is preferred.

[0015] Furthermore, the antitumor drug is selected from one or more of AMG510, MRTX849 and / or ARS1620; preferably AMG510.

[0016] Furthermore, the pharmaceutical composition also includes pharmaceutically acceptable salts or esters.

[0017] Furthermore, the pharmaceutical salts mentioned include, but are not limited to, pharmaceutical salts such as acetates and hydrochlorides.

[0018] Furthermore, the pharmaceutically defined esters include, but are not limited to, decanoates.

[0019] Furthermore, one or more pharmaceutically acceptable carriers or excipients may be added to the pharmaceutical composition.

[0020] Furthermore, the pharmaceutical composition can be formulated into various forms such as injection, tablets, powder, granules, capsules, oral liquid, injectable preparations, or aerosols; all of the above dosage forms can be prepared according to conventional methods in the pharmaceutical field.

[0021] Furthermore, the formulation may be one or more of a conventional formulation, a sustained-release formulation, a controlled-release formulation, and / or a variety of microparticle delivery systems.

[0022] Furthermore, the tablets can widely utilize a variety of carriers known in the art, including one or more of diluents and absorbents, humectants and binders, disintegrants, disintegration inhibitors, absorption promoters and / or lubricants.

[0023] Furthermore, the diluent and absorbent include, but are not limited to, one or more of starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, and / or aluminum silicate.

[0024] Furthermore, the wetting agent and adhesive include, but are not limited to, one or more of water, glycerin, polyethylene glycol, ethanol, propanol, starch paste, dextrin, syrup, honey, glucose solution, gum arabic paste, gelatin paste, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and / or polyvinylpyrrolidone.

[0025] Furthermore, the disintegrant includes, but is not limited to, one or more of the following: dried starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitol fatty acid ester, sodium dodecyl sulfonate, methylcellulose and / or ethylcellulose.

[0026] Furthermore, the disintegration inhibitors include, but are not limited to, sucrose, tristearate, cocoa butter, and / or hydrogenated oils.

[0027] Furthermore, the absorption enhancer includes, but is not limited to, one or more of quaternary ammonium salts and / or sodium dodecyl sulfate.

[0028] Furthermore, the lubricant includes, but is not limited to, one or more of talc, silica, corn starch, stearate, boric acid, liquid paraffin, and / or polyethylene glycol.

[0029] Furthermore, the tablets can be further formulated into coated tablets, including sugar-coated tablets, film-coated tablets, enteric-coated tablets, bilayer tablets, and multilayer tablets.

[0030] Furthermore, the injectable formulation includes, but is not limited to, one or more of the following: solutions, emulsions, lyophilized powder for injection, and / or suspensions.

[0031] Furthermore, the injectable formulation may use all diluents commonly used in the art, including but not limited to one or more of water, ethanol, polyethylene glycol, 1,3-propanediol, ethoxylated isostearyl alcohol, polyoxyethylene isostearyl alcohol, and / or polyoxyethylene sorbitan fatty acid esters.

[0032] Furthermore, in order to prepare an isotonic injection solution, appropriate amounts of one or more of sodium chloride, glucose, glycerol, conventional solubilizers, buffers, and / or pH adjusters may be added to the injectable formulation.

[0033] Furthermore, colorants, preservatives, flavorings, tasters, sweeteners, or other materials may be added to the pharmaceutical preparations if necessary.

[0034] Furthermore, the pharmaceutical composition can be introduced into the body, such as through muscles, intradermal tissue, subcutaneous tissue, or veins, via physical or chemical means.

[0035] Thirdly, the present invention provides the use of the sugar polymer nanoparticles as described in the first aspect or the pharmaceutical composition as described in the second aspect in the preparation of an antitumor drug, said use comprising at least one of the following effects:

[0036] (1) Reprogramming the tumor microenvironment;

[0037] (2) Increase the penetration of drugs into tumors;

[0038] (3) Treating cancer.

[0039] Furthermore, the antitumor drug is selected from one or more of AMG510, MRTX849 and / or ARS1620; preferably AMG510.

[0040] Furthermore, the pharmaceutical composition also includes pharmaceutically acceptable salts or esters.

[0041] Furthermore, the pharmaceutical salts mentioned include, but are not limited to, pharmaceutical salts such as acetates and hydrochlorides.

[0042] Furthermore, the pharmaceutically defined esters include, but are not limited to, decanoates.

[0043] Furthermore, one or more pharmaceutically acceptable carriers or excipients may be added to the pharmaceutical composition.

[0044] Furthermore, the pharmaceutical composition can be formulated into various forms such as injection, tablets, powder, granules, capsules, oral liquid, injectable preparations, or aerosols; all of the above dosage forms can be prepared according to conventional methods in the pharmaceutical field.

[0045] Furthermore, the formulation may be one or more of a conventional formulation, a sustained-release formulation, a controlled-release formulation, and / or a variety of microparticle delivery systems.

[0046] Furthermore, the tablets can widely utilize a variety of carriers known in the art, including one or more of diluents and absorbents, humectants and binders, disintegrants, disintegration inhibitors, absorption promoters and / or lubricants.

[0047] Furthermore, the diluent and absorbent include, but are not limited to, one or more of starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, and / or aluminum silicate.

[0048] Furthermore, the wetting agent and adhesive include, but are not limited to, one or more of water, glycerin, polyethylene glycol, ethanol, propanol, starch paste, dextrin, syrup, honey, glucose solution, gum arabic paste, gelatin paste, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and / or polyvinylpyrrolidone.

[0049] Furthermore, the disintegrant includes, but is not limited to, one or more of the following: dried starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitol fatty acid ester, sodium dodecyl sulfonate, methylcellulose and / or ethylcellulose.

[0050] Furthermore, the disintegration inhibitors include, but are not limited to, sucrose, tristearate, cocoa butter, and / or hydrogenated oils.

[0051] Furthermore, the absorption enhancer includes, but is not limited to, one or more of quaternary ammonium salts and / or sodium dodecyl sulfate.

[0052] Furthermore, the lubricant includes, but is not limited to, one or more of talc, silica, corn starch, stearate, boric acid, liquid paraffin, and / or polyethylene glycol.

[0053] Furthermore, the tablets can be further formulated into coated tablets, including sugar-coated tablets, film-coated tablets, enteric-coated tablets, bilayer tablets, and multilayer tablets.

[0054] Furthermore, the injectable formulation includes, but is not limited to, one or more of the following: solutions, emulsions, lyophilized powder for injection, and / or suspensions.

[0055] Furthermore, the injectable formulation may use all diluents commonly used in the art, including but not limited to one or more of water, ethanol, polyethylene glycol, 1,3-propanediol, ethoxylated isostearyl alcohol, polyoxyethylene isostearyl alcohol, and / or polyoxyethylene sorbitan fatty acid esters.

[0056] Furthermore, in order to prepare an isotonic injection solution, appropriate amounts of one or more of sodium chloride, glucose, glycerol, conventional solubilizers, buffers, and / or pH adjusters may be added to the injectable formulation.

[0057] Furthermore, colorants, preservatives, flavorings, tasters, sweeteners, or other materials may be added to the pharmaceutical preparations if necessary.

[0058] Furthermore, the pharmaceutical composition can be introduced into the body, such as through muscles, intradermal tissue, subcutaneous tissue, or veins, via physical or chemical means.

[0059] Beneficial effects

[0060] This invention encapsulates the anticancer drug AMG510 in mannose, which can reprogram the tumor microenvironment and increase drug penetration into the tumor. The synthesized glycopolymer nanoparticles AMG510@M-NP are hydrophilic and easily absorbed in vivo, reducing the actual dosage required at the theoretical drug level and further mitigating adverse drug reactions. Mannose and AMG510 exhibit a synergistic effect, enhancing the anticancer efficacy. Furthermore, mannose is readily available, the preparation process is simple, costs are reduced, and it is suitable for mass production. Attached Figure Description

[0061] Figure 1 The NMR spectrum of 2′-bromoethylmannose is 1H NMR.

[0062] Figure 2 The NMR spectrum of 2′-bromoethylglucose is 1H NMR.

[0063] Figure 3 The NMR spectrum of 2′-aminoethylmannose is 1H NMR.

[0064] Figure 4 The NMR spectrum of 2′-aminoethylglucose is 1H NMR.

[0065] Figure 5 GPC curves for PtBMA were obtained using tetrahydrofuran as the mobile phase.

[0066] Figure 6 For PtBMA and PMAA nuclear magnetic resonance proton spectrum analysis.

[0067] Figure 7 PMAA in d6-DMSO 1 H NMR spectrum.

[0068] Figure 8 For PMAN in d6-DMSO 1 HNMR spectrum.

[0069] Figure 9 For PGlc in d6-DMSO 1 H NMR spectrum.

[0070] Figure 10 The particle size and morphology of AMG510 nanoparticles after being coated with AMG510 are shown.

[0071] Figure 11 This refers to the tumor's invasive ability.

[0072] Note: (A) Immunofluorescence colocalization entity map, green - phalloidin cytoskeleton, blue - AMG510 drug; (B) Immunofluorescence colocalization statistical map, *** indicates p-value <0.0001.

[0073] Figure 12 The sugar nanoparticles can further kill tumors through the immune system.

[0074] Note: (A) Schematic diagram of tumor-bearing and treatment in nude mice; (B) Schematic diagram of mouse tumor and statistical graph, * indicates p value < 0.05; (C) Schematic diagram of tumor-bearing and treatment in Balbc mice; (D) Schematic diagram of mouse tumor and statistical graph, * indicates p value < 0.05. Detailed Implementation

[0075] The specific embodiments of the present invention will be further described below. It should be noted that these descriptions are for the purpose of aiding understanding the present invention, but do not constitute a limitation thereof. Furthermore, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0076] Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods, and the experimental materials used in the following embodiments are all available through conventional commercial channels.

[0077] Terminology Explanation

[0078] Tumor bearing in mice: This refers to the process of transplanting tumor cells into mice, allowing them to form tumor tissue. This experimental method is widely used in tumor research to assess the proliferative capacity of tumor cells, drug efficacy, and immune system response. Tumor bearing procedure: The prepared tumor cell suspension is injected subcutaneously or at other sites into the mouse. Common injection sites include the flank, armpit, or back. Before injection, the injection site should be disinfected with an alcohol swab, and the tumor cell suspension should be injected slowly to prevent leakage or premature extravasation.

[0079] AMG510, also known as Sotorasib, is a targeted drug for KRAS G12C mutations, primarily used to treat patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) harboring KRAS G12C mutations.

[0080] SW1463 is a cell line derived from a 66-year-old Caucasian woman with colorectal adenocarcinoma. It exhibits an epithelial morphology and was primarily isolated from colonic and rectal tissues. This cell line is suitable for cancer research, exhibiting adherent growth and showing negative results for bacteria, yeast, and mycoplasma in sterility tests.

[0081] SW1463 is a cell line derived from human rectal adenocarcinoma, initially isolated from the rectum of a 66-year-old Caucasian woman with colorectal adenocarcinoma. This cell line exhibits an epithelial-like morphology and adherent growth characteristics. The SW1463 cell line is frequently used in cancer research, particularly in investigating radiation resistance and tumor reproliferation in colorectal cancer.

[0082] CT26 -KRASG12C Tumor cells: This is a model cell line generated by introducing a KRASG12C mutation into the mouse colon cancer cell line CT26 using CRISPR / Cas9 technology. This mutation leads to the continued activation of the KRAS protein, thereby promoting the proliferation and survival of tumor cells. Studies have shown that AMG510 (a KRASG12C inhibitor) can significantly inhibit the growth of these tumor cells, and when used in combination with anti-PD-1 immunotherapy, it can further enhance the anti-tumor effect, even achieving complete tumor regression in some mice.

[0083] BALB / c mice are an inbred mouse strain widely used in scientific research. Their origins can be traced back to 1913 when Dr. H.J. Bagg purchased white mice from Ohio, USA, and conducted isolated breeding and behavioral studies. In 1923, E. Carleton MacDowell obtained these mice from Bagg and began inbreeding, naming the 26th generation in 1932 BALB / c. BALB / c mice are commonly used in immunology, oncology, physiology, nuclear medicine research, and monoclonal antibody production.

[0084] Experimental materials

[0085] CPDB: 2-Cyano-2-propylbenzodisulfide.

[0086] tBMA: tert-butyl methacrylate.

[0087] AIBN: Azobisisobutyronitrile.

[0088] TFA: Trifluoroacetic acid.

[0089] Palladium / carbon: 10% palladium, 55% water content.

[0090] TA: Tyramine hydrochloride.

[0091] EDC: Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride.

[0092] NHS: N-hydroxysuccinimide.

[0093] SW837 cell line, purchased from the official website of the Chinese Academy of Sciences.

[0094] SW1463 cell line, purchased from the official website of the Chinese Academy of Sciences.

[0095] CT26 -KRASG12C Tumor cells, CT26.WT, were purchased from the official website of the Chinese Academy of Sciences and subsequently subjected to crispr-cas9 gene editing to mutate KRAS G12V to KRAS G12C.

[0096] Balb / c mice and thymic nude mice aged 4-6 weeks were acclimatized for one week before the experiment.

[0097] Example 1: Amino-modified mannose and glucose

[0098] The synthetic route for amino-modified mannose and glucose includes the following steps:

[0099]

[0100] A. Synthesis of 2′-bromoethyl sugar

[0101] (1) Mix mannose or glucose (3.0g, 16.7mmol) with H2SO4-silica (120mg);

[0102] (2) Add 15 mL of 2-bromoethanol to the system of (1);

[0103] (3) Pass argon gas into the mixed solution (2) and stir at 60°C;

[0104] (4) The product of (3) was purified by silica gel column chromatography;

[0105] Excess 2-bromoethanol was washed away with DCM, followed by column elution with DCM:MeOH (v / v = 5:1) to obtain pure 2'-bromoethyl-mannose or glucose product 2'-bromoethyl sugar (e.g. Figure 1 and Figure 2 (As shown).

[0106] Synthesis of B,2′-Aldylethyl sugar

[0107] (1) Dissolve 2′-bromoethyl sugar (2g, 7.0mmol) in DMF and add sodium azide (0.91g, 14mmol);

[0108] (2) Stir the system in (1) at 80°C overnight to obtain the product;

[0109] (3) The product in (2) can be obtained by filtration and drying to obtain 2′-azidoethyl sugar.

[0110] Synthesis of C,2′-aminoethyl sugar

[0111] (1) Dissolve the 2′-azidoethyl sugar obtained in B in anhydrous methanol and add palladium on carbon catalyst;

[0112] (2) The reaction atmosphere in (1) is made into hydrogen by replacing the gas multiple times;

[0113] (3) TLC detection of the raw materials confirmed that the reaction was complete;

[0114] (4) Adjust the pH of the mixture to neutral using ion exchange resin;

[0115] (5) Filter to remove impurities, and evaporate the filtrate to obtain 2′-aminoethyl sugar.

[0116] like Figure 3 The image shown is the 1H NMR spectrum of 2′-aminoethylmannose; as shown... Figure 4 The image shown is the 1H NMR spectrum of 2′-aminoethylglucose.

[0117] Example 2 Synthesis of Sugar Polymers

[0118] Synthetic route of the sugar polymer: The polymerization part adopts a reversible addition-fragmentation chain transfer polymerization method, and then sugar and tyramine are modified into the polymer backbone by post-grafting. First, polytert-butyl methacrylate (PtBMA) is prepared, and then the tert-butyl protecting group in PIBMA is hydrolyzed with trifluoroacetic acid (TFA) to obtain polymethacrylic acid (PMAA).

[0119] The synthetic route for preparing manno / glucose polymers by RAFT polymerization includes the following steps:

[0120]

[0121] A. Synthesis of PtBMA

[0122] (1) The commercially available RAFT chain transfer agent 2-cyano-2-propylbenzodisulfide CPDB (0.220 g, 0.001 mol), monomer

[0123] tBMA (20.406 g, 143.50 mmol) and initiator AIBN (0.041 g, 0.25 mmol) were dissolved in a polymerization flask;

[0124] (2) The system dissolved in (1) was subjected to freezing-deoxygenation-thawing operation, circulated and then sealed for polymerization reaction;

[0125] (3) After (2) reaction is complete and the reaction is quenched by liquid nitrogen, the mixture is precipitated into pre-cooled water / methanol (3 / 1, v / v);

[0126] (4) Repeat the precipitation operation, filter and collect the filter cake, and vacuum dry to obtain a light pink solid, which is PtBMA.

[0127] like Figure 5 As shown, the GPC curve of PtBMA was tested using tetrahydrofuran as the mobile phase. The GPC analysis results of the product PtBMA were: Mn = 12.1 kg / mol and the polydispersity index (Mw / Mn, M / M) of the molecular weight distribution was 1.14.

[0128] B. Synthesis of PMAA

[0129] (1) Weigh out the PtBMA prepared in A and dissolve it in DCM;

[0130] (2) Add TFA to the solution in (1) and let it react;

[0131] (3) After the reaction in (2) is complete, concentrate the reaction solution under reduced pressure and transfer the product to a dialysis bag for dialyzing in deionized water;

[0132] (4) After the dialysis in (3) is completed, freeze dry to obtain the product PMAA.

[0133] like Figure 6 and Figure 7 As shown, PtBMA in CDCl3 and PMAA in d6-DMSO 1 1H NMR spectra showed that the proton signal of tert-butyl disappeared after hydrolysis, proving that the hydrolysis was complete. 1H NMR analysis confirmed that the TFA completely hydrolyzed the tert-butyl group.

[0134] Synthesis of C.PMan

[0135] (1) Weigh the PMAA prepared in B and mix it with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC).

[0136] N-hydroxysuccinimide (NHS) is dissolved in DMF and reacted.

[0137] (2) Add amino-modified sugar (Saccharide-NH2) and tyramine hydrochloride (TA) to the system of (1), and continue the reaction to obtain the product;

[0138] (3) Transfer the product from (2) to a dialysis bag and dialyze it in deionized water;

[0139] (4) After dialysis in (3) is completed, freeze-dry the sample and name the sugar polymers prepared using mannose and glucose respectively.

[0140] PMan and PGlc.

[0141] like Figure 8 and Figure 9 As shown, the sugar polymers prepared using mannose and glucose were named PMan and PGlc, respectively. According to the 1H NMR spectroscopy analysis, the carboxyl group in PMAA was completely reacted, and the modification ratio of sugar to tyramine in the obtained sugar polymers was approximately 4 / 1.

[0142] Example 3: Formation of AMG510 encapsulated in sugar nanoparticles

[0143] Nanoparticles are obtained using a nanoprecipitation method, which includes the following steps:

[0144] The sugar polymer and AMG510 were dissolved in DMSO and then added to water. Due to the hydrophobicity of AMG510, it was encapsulated within the core of the nanoparticles.

[0145] Mannose polymer and AMG510 were dissolved in DMSO and then added together to water to form mannose polymer nanoparticles AMG510@M-NP.

[0146] Glucose polymer and AMG510 were dissolved in DMSO and then added together to water to form glucose polymer nanoparticles AMG510@G-NP.

[0147] like Figure 10 As shown, the particle size of the two nanoparticles encapsulated with AMG510 was characterized by dynamic light scattering test; the particle size range was 80nm-100nm; the small particle size of the drug makes it easy to swallow and improves patient compliance.

[0148] Example 4 Drug Loading

[0149] A. Solvent displacement method for preparing AMG510-encapsulated glycopolymer nanoparticles

[0150] AMG510-encapsulated glycopolymer nanoparticles were prepared using a solvent displacement method. Taking AMG510@M-NP as an example, the preparation method includes the following steps:

[0151] (1) Dissolve PMan and AMG510 in DMSO (PMan 20 mg / mL);

[0152] (2) After the solution in (1) is mixed evenly, add it dropwise to deionized water and put it into a dialysis bag;

[0153] (3) Dialyze in deionized water in the dark, and change the dialysis medium every 4 hours;

[0154] (4) After dialysis, the nanoparticles containing AMG510 were freeze-dried.

[0155] B. Determining drug loading

[0156] To determine the drug loading capacity of nanoparticles, the nanoparticles were decomposed using DMSO. The specific method includes the following steps:

[0157] (1) The nanoparticles were destroyed by DMSO and AMG510 was extracted;

[0158] (2) The fluorescence intensity of AMG510 was measured using a fluorescence spectrophotometer;

[0159] (3) The drug concentration was calculated using a standard curve.

[0160] Drug loading and encapsulation efficiency are calculated using the following formulas:

[0161] Drug loading (wt.%) = (Weight of loaded drug / (Weight of polymer + Weight of loaded drug)) × 100;

[0162] Encapsulation rate (%) = (weight of drug loaded / total amount of drug) × 100.

[0163] C. Test Results

[0164] The drug loading of AMG510@M-NP was 10.3%, with an encapsulation efficiency of 76.4%; the drug loading of AMG510@G-NP was 10.0%, with an encapsulation efficiency of 73.9%.

[0165] D. Comparison with finished drugs

[0166] (1) Commonly available AMG510 models on the market:

[0167] The Lucius Pharmaceuticals-manufactured version of sotorasibol is available in a strength of 56 tablets (120mg each). For example, if the theoretical dosage is 96mg / day, the actual dosage is 960mg / day.

[0168] Without the encapsulation of a glycopolymer nanocarrier, AMG510 is poorly absorbed. To achieve the desired effect, an excessive dose of the drug is required. That is, the actual amount of drug ingested is 960mg, resulting in a large amount of unabsorbed drug, which is wasteful and accumulates in the body, leading to more adverse reactions.

[0169] (2) The AMG510@M-NP of this application:

[0170] The drug loading capacity of this nanomedicine is approximately 10%. For example, when the theoretical dosage is 96 mg / day, 960 mg of AMG510@M-NP actually needs to be taken orally. The actual drug content in the body is 96 mg. After the material encapsulates the AMG510 drug, its hydrophilicity is improved, its absorption capacity is enhanced, waste is reduced, and the risk of adverse drug reactions is lowered.

[0171] The specific dosage is based on the opinion of the clinician and can be adjusted flexibly. Even with a small dosage, the conditions can still be met, and the required dosage can be reduced in actual application by reducing the drug load.

[0172] In addition, mannose plays an important role in the energy metabolism and biosynthesis of tumor cells and has the effect of inhibiting the growth of malignant tumors. In the synthesized AMG510@M-NP, mannose and AMG510 have a synergistic effect, which enhances the anti-cancer effect.

[0173] Example 5 Cell Infiltration Ability

[0174] A. Immunofluorescence co-localization

[0175] (1) The SW837 and SW1463 cell lines that have grown to the logarithmic phase were seeded in cell culture dishes;

[0176] (2) Add 0.1 μM AMG510 or AMG510@M-NP to the two cell lines in (1), respectively.

[0177] AMG510@G-NP was incubated.

[0178] (3) Fix the cells with paraformaldehyde and draw circles around the evenly distributed area of ​​the cells using an immunohistochemical pen.

[0179] (4) Add 50-100 μL of membrane permeation solution to the system in (3) and incubate;

[0180] (5) Wash the glass slides;

[0181] (6) Add diluted Phalloidin solution to the marked area in (3) and incubate in a dark room;

[0182] (7) After washing and drying, seal the film with anti-fading mounting solution;

[0183] (8) Use a confocal microscope to capture fluorescence images.

[0184] B. Test Results

[0185] Fluorescence images were captured, with AMG510 excitation wavelengths of 370-400 nm and Phalloidin excitation wavelengths of 465-495 nm.

[0186] like Figure 11 As shown, the number of encapsulated drugs entering tumor cells increases. Figure 11 As shown in Figure A, green represents the cytoskeleton, and blue represents the AMG510 drug. Figure 11The statistical graph in B shows that the number of AMG510@M-NP cells entering tumor cells was significantly greater than that of AMG510 alone.

[0187] Example 6 Tumor Killing Ability

[0188] A. Tumor cell modification

[0189] The target sites of the KRAS G12C mutant guide RNA (sgRNA) were selected using the guide RNA prediction tool provided from the Professor Feng Zhang Laboratory website (http: / / crispr.mit.edu).

[0190] The selected sgRNA sequence for targeting the KRAS G12C site is:

[0191] GACTGAGTATAAACTTGTGA.

[0192] sgRNA oligonucleotides were synthesized, cloned, and introduced into the lenti-CRISPR-V2 vector. A single-stranded oligodeoxynucleotide (ssODN) was designed as a homologous donor to repair the sgRNA cleavage site. This ssODN introduced a cysteine ​​codon at position 12 (GAT:aspartate changed to TGT:cysteine) and added a silent mutation to prevent further cleavage.

[0193] The ssODN sequence is as follows:

[0194] ATGTTCTAATTTAGTTGTATTTTATTATTTTTATTGTAAGGCCTGCTGAAAATGACTGAGT

[0195] ATAAATTAGTCATGGTTGGAGCTTGTGGCGTAGGCAAGAGCGCCTTGACGATACAGCT AATTCAGAATCACTTTGTGGATGAGTACGACCCTACGATAGAGGTAACGCT.

[0196] After passage, CT26 cells in the logarithmic growth phase were sporulated at a rate of 1×10⁻⁶. 6 Cells per well are seeded in the well plate at a density of 100 cells / well;

[0197] Transfection was performed using lenti-CRISPR-V2 vector and ssODN.

[0198] After transfection, the cells underwent preliminary puromycin selection;

[0199] After selection with puromycin, the cells were limitedly diluted, and approximately 50-100 cells were seeded into well plates.

[0200] Isolate KRAS knock-in clones;

[0201] The amplified KRAS KI clone was used to detect the KRAS G12C mutation.

[0202] Genomic DNA was extracted from the selected clones, and PCR amplification of the G12C mutation site was performed using designed primers. The PCR primers used were:

[0203] Forward primer -GTGTGTCCACAGGGTATAGCGTACT;

[0204] Reverse primer -CACCTATGGTTCCCTAACACCCAG.

[0205] High molecular weight genomic DNA was isolated from mouse tumor tissue and extracted. The quality of the DNA was assessed, and samples with a score of A or B+ were selected for further sequencing.

[0206] B. Test Methods

[0207] (1) CT26 -KRASG12C Tumor cells were seeded into 1640 medium containing 10% serum and cultured until the cell confluence reached 70-80%.

[0208] (2) Centrifuge the cells from (1) and collect the tumor cells;

[0209] (3) Resuspend the tumor cells collected in (2) in PBS, continue centrifugation, collect tumor cells, and repeat this process; (4) Resuspend the tumor cells collected in (3) in PBS, count them, and adjust the concentration to 5×10⁻⁶. 6 Cells / mL; (5) Shave and disinfect 4-6 week old Balb / c mice and athymic nude mice, and subcutaneously inject (4) into the left groin area.

[0210] The number of cells injected was 1×103 6 Each injection unit has an injection volume of 200 μL.

[0211] (6) Starting from day 15 after inoculation, the mice in (5) were divided into four groups and administered physiological saline and AMG510 (M-NP) orally every day.

[0212] Or glucose nanoparticles (G-NP), at a dose of 30 mg / kg;

[0213] (7) The tumor was measured every 3 days. The length and width of the tumor were measured with calipers and the result was expressed using the formula: (length x width). 2 / 2

[0214] To calculate tumor volume.

[0215] C. Test Results

[0216] Tumors were implanted subcutaneously in two types of mice, and treatment trials were conducted using three different methods (as shown in Table 1). The control group received oral saline.

[0217] The cytotoxic effects of AMG510 coated with mannose and glucose (AMG510@M-NP and AMG510@G-NP, respectively) were significantly better than those of AMG510 alone. Figure 12 (AB) This indicates that in mice, AMG510 encapsulated in nanomaterials also exhibited better tumor infiltration ability and more effectively killed tumors. However, there was no significant difference between the two nanomaterial-encapsulated AMG510 formulations.

[0218] In immunocompetent Balbc mice, AMG510@M-NP was significantly more effective than AMG510@G-NP. Figure 12 (CD). This result indicates that AMG510@M-NP can activate the immune system to further kill tumor cells.

[0219] Table 1. Tumor killing ability of the treatment group

[0220]

[0221]

Claims

1. A sugar polymer nanoparticle, wherein the sugar polymer nanoparticle is AMG510@M-NP; wherein, AMG510 is used to treat KRAS. G12C A drug for colorectal cancer caused by mutations, where M is a mannose polymer and NP is nanoparticles formed from the two; the structural formula of the mannose polymer is as follows: 。 2. A pharmaceutical composition comprising the glycopolymer nanoparticles as described in claim 1.

3. The pharmaceutical composition of claim 2, wherein one or more pharmaceutically acceptable carriers are incorporated into the pharmaceutical composition.

4. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is formulated as an injection, tablet, powder, granule, capsule, or oral liquid.

5. The sugar polymer nanoparticles of claim 1 in the preparation of therapeutic KRAS G12C Application in drugs for colorectal cancer caused by mutations.